By 2018 we anticipate the nucleic acid technology market will have matured as many of the late-stage clinical programmes come to fruition and drug delivery companies continue to overcome issues ...

Nucleic acid therapies offer targeted treatment for genetic diseases, but delivery remains a key hurdle. Explore how advances ...

Just a few short months after the biotech’s nucleic acid delivery tech helped land a deal with BioMarin, the Edmonton, Alberta-based Canadian company has teamed up with Eli Lilly for $50 million ...

Surface-engineered LNPs, propelled by clinical successes like patisiran and mRNA vaccines, enable targeted nucleic acid delivery via ligands (antibodies, peptides) and conjugation chemistries (click ...

It is estimated that nucleic acid aptamer market will reach nearly $5.4 billion by 2020, with a compound annual growth rate (CAGR) of 73.5% from 2015 to 2020.

It also secured an undisclosed amount of funding from the Bill & Melinda Gates Foundation to expand its work on cell-targeted delivery of nucleic acid-based drugs, and was identified by The Sunday ...

The development of efficient delivery technologies has lagged behind significant advancements in nucleic acid therapeutics, such as antisense oligonucleotids (ASOs), short interfering RNA (siRNA ...

A research team led by Associate Professor Tomohide Takaya along with Ms. Rena Ikeda, Chihaya Kimura, Dr. Yuma Nihashi, Dr. Koji Umezawa, and Dr. Takeshi Shimosato from the Faculty of Agriculture ...